LRIT3: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of LRIT3. The page also collects GeneMedi's different modalities and formats products for LRIT3 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the LRIT3 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Introcelluar Protein.
This gene encodes a protein that has a fibronectin type III domain and a C-terminal transmembrane domain, as well as a leucine-rich repeat domain and immunoglobulin-like domain near the N-terminus. The encoded protein may regulate fibroblast growth factor receptors and affect the modification of these receptors, which are glycosylated differently in the Golgi and endoplasmic reticulum. Mutations in this gene are associated with congenital stationary night blindness, type 1F. [provided by RefSeq, May 2013]
Target ID | GM-IP1110 |
Target Name | LRIT3 |
Gene ID | 345193,242235,502596,698360,610534,101083079,511618,100072841 |
Gene Symbol and Synonyms | CSNB1F,FIGLER4,Gm421,LRIT3,RGD1559637 |
Uniprot Accession | Q3SXY7 |
Uniprot Entry Name | LRIT3_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Cytokine Target |
Disease | N/A |
Gene Ensembl | ENSG00000183423 |
Target Classification | N/A |
Pre-made anti-LRIT3 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-LRIT3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-LRIT3 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-LRIT3 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | Cytokine antibody | Detail |
Recombinant multi-species LRIT3/ CSNB1F/ FIGLER4 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine LRIT3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
LRIT3 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |
Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 is a protein that in humans is encoded by the LRIT3 gene.
Target | Species | Antigen Product Name | Bioactivity validation of Antigen | Antibody Product Name | Bioactivity validation of Antibodies | Detail |
LRIT3 | Human, Cynomolgus/Rhesus macaque, rat, mouse | leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3) protein | Affintiy&bioactivity validated by ELISA, cell culture validated | Anti-LRIT3 monoclonal antibody | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). | Detail |
Click to check more Cytokine Products